Department of Integrative Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Chin J Integr Med. 2011 Feb;17(2):141-5. doi: 10.1007/s11655-011-0630-5. Epub 2011 Mar 9.
To investigate the effect of dexamethasone (Dx) combined with modified Dachengqi Decoction (DCQD), a Chinese herbal decoction for purgation, on patients with severe acute on patients with severe acute, a Chinese herbal decoction for purgation, on patients with severe acute pancreatitis (SAP) accompanied with systematic inflammatory response syndrome (SIRS).
A total of 81 patients diagnosed as SAP were randomly assigned to a control group or treatment group according to a random number table generated from an SPSS software. The patients in the control group (38 cases) received standard treatment and Chinese herbal decoction for purgation; those in the treatment group (43 cases) received additional 1 mg/(kg·d) dexamethasone (Dx) treatment for three days based on the above treatment. The mortality rate, acute respiratory distress syndrome (ARDS), renal failure, hemorrhage, sepsis, pancreatic pseudocyst, pancreatic abscess, operability, and days of hospitalization were compared between the two groups.
Three patients in the control group and eight patients in the treatment group dropped out from the study with a drop-out rate of 7.8% and 18.6%, respectively, and no statistics difference was shown between the two groups (P>0.05). Dx treatment significantly reduced ARDS rate and shortened the length of hospitalization compared to those in the control group (7/35, 20.0% versus 15/35, 42.9%, P=0.0394; 32.5±13.2 days versus 40.2±17.5 days, P=0.0344). Other parameters including the mortality rate were not significant different between the two groups.
Dx combined with DCQD could decrease the risk of developing ARDS in SAP patients with SIRS and shorten their length of hospitalization.
探讨地塞米松(Dx)联合大承气汤(DCQD)对伴有全身炎症反应综合征(SIRS)的重症急性胰腺炎(SAP)患者的影响。
采用随机数字表法将 81 例 SAP 患者分为对照组和治疗组,每组 43 例。对照组采用常规西医治疗+泻下中药,治疗组在对照组基础上加用 1mg/(kg·d)地塞米松(Dx)治疗 3d。比较两组患者死亡率、急性呼吸窘迫综合征(ARDS)、肾衰竭、出血、感染、胰腺假性囊肿、胰腺脓肿、手术可切除性和住院时间。
对照组脱落 3 例,治疗组脱落 8 例,两组患者的脱落率分别为 7.8%和 18.6%,差异无统计学意义(P>0.05)。与对照组相比,Dx 治疗组的 ARDS 发生率降低,住院时间缩短(7/35,20.0%比 15/35,42.9%,P=0.0394;32.5±13.2d 比 40.2±17.5d,P=0.0344)。两组患者死亡率等其他参数差异均无统计学意义。
地塞米松联合 DCQD 能降低 SAP 合并 SIRS 患者发生 ARDS 的风险,缩短住院时间。